Discovery of EGF Receptor Inhibitors That Are Selective for the d746‐750/T790M/C797S Mutant through Structure‐Based de Novo Design

Next‐generation epidermal growth factor receptor (EGFR) inhibitors against the d746‐750/T790M/C797S mutation were discovered through two‐track virtual screening and de novo design. A number of nanomolar inhibitors were identified using 2‐aryl‐4‐aminoquinazoline as the molecular core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746‐750/T790M/C797S mutant. Furthermore, some of these EGFR inhibitors showed a greater than 1000‐fold selectivity for the d746‐750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.     

Bifunctional Small‐Molecule Ligands of K‐Ras Induce Its Association with Immunophilin Proteins

Here we report the design, synthesis, and characterization of bifunctional chemical ligands that induce the association of Ras with ubiquitously expressed immunophilin proteins such as FKBP12 and cyclophilin A. We show this approach is applicable to two distinct Ras ligand scaffolds, and that both the identity of the immunophilin ligand and the linker chemistry affect compound efficacy in biochemical and cellular contexts. These ligands bind to Ras in an immunophilin‐dependent fashion and mediate the formation of tripartite complexes of Ras, immunophilin, and the ligand. The recruitment of cyclophilin A to GTP‐bound Ras blocks its interaction with B‐Raf in biochemical assays. Our study demonstrates the feasibility of ligand‐induced association of Ras with intracellular proteins and suggests it as a promising therapeutic strategy for Ras‐driven cancers.     

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands

The bromodomain-containing protein BRD9, a subunit of the human BAF (SWI/SNF) nucleosome remodeling complex, has emerged as an attractive therapeutic target in cancer. Despite the development of chemical probes targeting the BRD9 bromodomain, there is a limited understanding of BRD9 function beyond acetyl-lysine recognition. We have therefore created the first BRD9-directed chemical degraders, through iterative design and testing of heterobifunctional ligands that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex. Degraders of BRD9 exhibit markedly enhanced potency compared to parental ligands (10- to 100-fold). Parallel study of degraders with divergent BRD9-binding chemotypes in models of acute myeloid leukemia resolves bromodomain polypharmacology in this emerging drug class. Together, these findings reveal the tractability of non-BET bromodomain containing proteins to chemical degradation, and highlight lead compound dBRD9 as a tool for the study of BRD9.     

Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6

Cyclin‐dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA‐approved CDK4/6 inhibitors for treating patients with metastatic breast cancer. However, due to conservation of their ATP‐binding sites, development of selective agents has remained elusive. Here, we report imide‐based degrader molecules capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6. We were also able to tune the activity of these molecules against Ikaros (IKZF1) and Aiolos (IKZF3), which are well‐established targets of imide‐based degraders. We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degradation with dual CDK4/6 degradation produced enhanced anti‐proliferative effects compared to CDK4/6 inhibition, CDK4/6 degradation, or IKZF1/3 degradation. In summary, we report here the first compounds capable of inducing selective degradation of CDK4 and CDK6 as tools to pharmacologically dissect their distinct biological functions.     

Semisynthese. Chemie mit den Molekülen der Natur

In Semisynthesis complex molecules have to be manipulated in a chemoselective, regioselective, and stereoselective fashion, necessitating smart protective group operations and innovative synthesis development. Key are always easily accessible and suitable starting materials, especially intermediates which can be produced by biotechnological processes. An extensive synthetic construction of drug candidates carries high innovative and intellectual property protection potential, hence multistep semi‐ and even total syntheses are an integral part of modern industrial research and drug development. Not a long time ago, the complexity such realized would have been inconceivable, which profoundly illustrates the progress synthesis methodology has made. Semisynthesis always aims more toward focussed application, and hence its scientific contribution mostly cater to the elucidation of molecular correlations. Especially the study of cellular processes and their quantification will be stimulated in the future. Thereby semisynthesis will continue to bridge the key future areas of synthesis research and chemical biology.